# A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

> **NCT05464420** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2162 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT05464420
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-05-25
- **Target enrollment:** 2162 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464420, "A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05464420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*